Endothelin-Receptor Blockade in Coronary Heart Disease

• Status: Completed
• Trial end date: 2006-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Endothelin is a hormon that causes acute and chronic narrowing of heart vessels. The purpose of this study is to assess whether suppression of this activity by using two types of receptor antagonists can reduce this effect and thus improve blood supply of the heart muscle.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Medical University of Vienna
• Treatments: BQ 788

Criteria

Inclusion Criteria:

• coronary artey disease

• stable angina pectoris

• male and post-menopausal female patients

• age above 19 years

• able and willing to conform to the requirements of the study

• provided written informed consent

Exclusion Criteria:

• severe focal coronary stenosis

• visually calcified stenosis

• aorto-ostial lesion location and unprotected left main stenosis

• pre-menopausal female patients

• diabetes mellitus

• unstable angina pectoris and/or acute Q-wave myocardial infarctaion within the past 72 hours

• current vasoactive medication

• previous percutaneous transluminal revascularization at the site of the target lesion

• lesion which has extremely angulated segments >90%

• vessel with escessive tortuosity of the proximal segment

• severe hypotension

• severely reduced left ventricular function

• severe carotid stenosis

• patients with pace maker

• patients with elevated liver enzymes

• patients simultaneously participating in another device or drug study

• inability of unwillingness to comply with the study protocol